ELLORARXINE Trademark

Trademark Overview


On Friday, June 23, 2023, a trademark application was filed for ELLORARXINE with the United States Patent and Trademark Office. The USPTO has given the ELLORARXINE trademark a serial number of 98055920. The federal status of this trademark filing is REGISTERED as of Tuesday, July 23, 2024. This trademark is owned by Nevrargenics Limited. The ELLORARXINE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical compositions and preparations for the treatment of neuropathic pain, neurodegenerative diseases, neurological conditions, and degenerative brain diseases; pharmaceutical compositions and preparations for the treatment of schizophrenia, Amyotrophic lateral 15 sclerosis (ALS), Parkinson's disease, multiple sclerosis (MS), Alzheimer's disease, motor neurone disease, cognitive disorders, memory impairment, memory deficit, senile dementia, cognitive impairment, stroke, traumatic brain injury, epilepsy, and spinal cord injury; pharmaceutical compositions and preparations for the treatment of retinoic acid receptor mediated diseases; anti-inflammatory pharmaceuticals
ellorarxine

General Information


Serial Number98055920
Word MarkELLORARXINE
Filing DateFriday, June 23, 2023
Status700 - REGISTERED
Status DateTuesday, July 23, 2024
Registration Number7454536
Registration DateTuesday, July 23, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2024

Trademark Statements


Goods and ServicesPharmaceutical compositions and preparations for the treatment of neuropathic pain, neurodegenerative diseases, neurological conditions, and degenerative brain diseases; pharmaceutical compositions and preparations for the treatment of schizophrenia, Amyotrophic lateral 15 sclerosis (ALS), Parkinson's disease, multiple sclerosis (MS), Alzheimer's disease, motor neurone disease, cognitive disorders, memory impairment, memory deficit, senile dementia, cognitive impairment, stroke, traumatic brain injury, epilepsy, and spinal cord injury; pharmaceutical compositions and preparations for the treatment of retinoic acid receptor mediated diseases; anti-inflammatory pharmaceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 25, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNevrargenics Limited
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressDurham DH11TT
GB

Party NameNevrargenics Limited
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressDurham DH11TT
GB

Party NameNevrargenics Limited
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressDurham DH11TT
GB

Trademark Events


Event DateEvent Description
Tuesday, June 27, 2023NEW APPLICATION ENTERED
Friday, March 15, 2024NON-FINAL ACTION WRITTEN
Friday, March 15, 2024NON-FINAL ACTION E-MAILED
Friday, March 15, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 22, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 25, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 11, 2024ASSIGNED TO EXAMINER
Monday, April 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 7, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 23, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, July 23, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Friday, March 22, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 22, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED